세계의 ISH(In Situ Hybridization) 시장 : 인사이트, 경쟁 환경, 시장 예측(-2032년)
In Situ Hybridization - Market Insights, Competitive Landscape, and Market Forecast - 2032
상품코드:1656921
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
ISH(In Situ Hybridization) 시장 규모는 2024년에 16억 7,355만 달러에 달했습니다. 이 시장은 2025년부터 2032년까지 예측 기간 동안 7.12%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 28억 8,613만 달러에 달할 것으로 예상되며, in situ hybridization에 대한 수요는 주로 암과 유전성 질환의 유병률 증가로 인해 눈에 띄게 급증하고 있습니다. 또한, 신경 질환 및 감염성 질환의 추세도 이러한 수요를 더욱 촉진하고 있습니다. 이와 함께, 활발한 R&D 활동과 자금 조달은 in situ hybridization 시장의 성장 궤도를 촉진하는 중요한 요인으로 작용하고 있습니다. 이러한 성장 추세는 2025년부터 2032년까지 예측 기간 동안 지속되고 번창할 것으로 예상됩니다.
ISH는 다운증후군, 에드워드 증후군과 같은 선천성 질환의 진단에 사용됩니다. 조사를 통해 특정 유전자가 조직이나 기관에서 어떻게 발현되는지 분석하여 발생 과정과 질병, 생리적 기능의 관여를 밝힐 수 있습니다. 따라서 유전성 질환이나 희귀질환의 환자 수 증가는 시장 성장에 기여할 것으로 예상됩니다. 예를 들어, 세계경제포럼이 2023년 2월에 발표한 보고서에 따르면 2019년 약 4억 7,500만 명이 희귀질환을 앓고 있으며, 이는 전 세계 인구의 10%에 해당합니다. 향후 5년 이내에 약 1,520만 명이 희귀질환을 확인하기 위한 임상유전체 검사를 받을 것으로 예상됩니다.
Johnson & Johnson이 2023년 2월에 발표한 기사에 따르면, 2023년 현재 전 세계적으로 3억 명 이상이 희귀질환을 앓고 있는 것으로 추정됩니다. 형광 in situ hybridization(FISH)은 병리학자들이 염색체 이상으로 인한 질병 진단을 돕기 위해 사용하는 유전자 검사 기술입니다. 따라서 유전성 질환 및 희귀질환 증가는 in situ hybridization의 광범위한 사용에 기여하고 있으며, 이는 시장 성장을 가속할 것으로 예상됩니다.
세계보건기구(WHO)가 2022년 발표한 자료에 따르면, 2020년 전 세계적으로 유방암 약 226만 건, 폐암 221만 건, 대장암 193만 건, 전립선암 141만 건, 위암 109만 건이 보고되었습니다.
2021년 Global Cancer Observatory가 발표한 데이터에 따르면, 2020년 전 세계적으로 약 54만 4,352건의 비호지킨림프종과 8만 3,087건의 호지킨림프종이 보고되었습니다. 같은 자료에 따르면, 2020년 전 세계적으로 약 474,519건의 백혈병과 176,404건의 다발성 골수종 사례가 보고된 바 있으며, In situ hybridization은 암과 관련된 유전자 발현 변화 및 염색체 이상을 조사하고 잠재적인 진단 지표 및 치료 표적을 발견하는 데 유용한 도구로 활용되고 있습니다. 중재 표적 발굴에 도움을 주며 시장 성장을 가속하고 있습니다.
in situ hybridization(ISH)은 감염성 병원체를 검출하기 위해 실험실 의학과 분자 유전학 기술을 융합하여 감염성 병원균을 검출하는 기술입니다. 특히, 형광 in situ hybridization(FISH)은 세포 구조의 무결성을 유지하면서 다양한 시료 내의 뉴클레오티드 서열을 식별하고, 핀포인팅하는 데 도움이 됩니다. 세계보건기구(WHO)의 2022년 발표에 따르면, 2022년에는 전 세계적으로 약 3억 5,400만 명이 B형 또는 C형 간염에 감염된 것으로 추정됩니다.
정부의 지원과 자금은 희귀질환 파트너십에서 얻을 수 있는 가치를 극대화하는 데 초점을 맞추고 있으며, 종합적인 목표는 희귀질환 분야의 연구와 혁신 수준을 향상시키는 것입니다. 예를 들어, 2023년 9월 영국의 연구 및 혁신 부문은 희귀질환 연구 촉진을 위한 다양한 이니셔티브에 총 7억 9,850만 달러(6억 2,700만 파운드)를 투자할 예정입니다. 특히 2016년부터 2021년까지 1억 2,690만 달러(9,970만 파운드)가 MRC 펠로우십과 NIHR 경력개발상(NIHR Career Development Award)에 배정되어 희귀질환 연구를 위한 종합적인 지원 네트워크가 구축되어 있습니다.
세계의 ISH(In Situ Hybridization)(in situ hybridization) 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별, 기술별, 용도별, 최종사용자별, 지역별 동향, 시장에 진출한 기업 프로파일 등의 정보를 전해드립니다.
목차
제1장 ISH(In Situ Hybridization) 시장 보고서 서론
제2장 ISH(In Situ Hybridization) 시장 주요 요약
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 ISH(In Situ Hybridization) 시장의 주요 요인 분석
ISH(In Situ Hybridization) 시장 성장 촉진요인
ISH(In Situ Hybridization) 시장 성장 억제요인과 과제
ISH(In Situ Hybridization) 시장 기회
제6장 ISH(In Situ Hybridization) 시장 : Porter의 Five Forces 분석
제7장 ISH(In Situ Hybridization) 시장 평가
제품 유형별
기기
시약 및 키트
소프트웨어
기술별
Fluorescence In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization (CISH)
기타
용도별
암 진단
유전성 질환
감염증
최종사용자별
병원 및 진료소
진단센터
제약회사 및 바이오테크놀러지 기업
학술기관 및 정부기관
지역별
북미
유럽
아시아태평양
기타 지역
제8장 ISH(In Situ Hybridization) 시장 기업과 제품 개요
Abbott Laboratories
Agilent Technologies, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
PerkinElmer Inc.
Sysmex Corporation
Biocare Medical, LLC
Genemed Biotechnologies, Inc.
NeoGenomics Laboratories
Advanced Cell Diagnostics, Inc.
BioView
Bio-Rad Laboratories, Inc.
Bio-Techne
QIAGEN
BioGenex
ZYTOVISION GmbH
Promega Corporation
Illumina, Inc.
Danaher Corporation
제9장 KOL(Key Opinion Leader)의 견해
제10장 프로젝트 접근
제11장 DelveInsight에 대해
제12장 면책사항과 문의
LSH
영문 목차
영문목차
In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of cancer and genetic diseases and increasing incidences of neurological disorders and infectious disease
The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032. The demand for in situ hybridization is witnessing a notable surge, driven predominantly by the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.
In Situ Hybridization Market Dynamics:
ISH is used to diagnose congenital diseases such as Down's syndrome and Edward's Syndrome. It enables researchers to analyze how certain genes are expressed in tissues or organs, shedding light on their involvement in developmental processes, diseases, and physiological functions. Therefore, the rising number of people affected by genetic or some kind of rare disease is expected to contribute to the growth of the market. For instance, a report by the World Economic Forum in February 2023, stated that approximately 475 million individuals were suffering from rare conditions in 2019 which comprised 10% of the global population. Within the upcoming five years, it was anticipated that around 15.2 million people were expected to undergo clinical genomic testing specifically aimed at identifying rare conditions.
According to an article shared by Johnson & Johnson in February 2023, the estimate suggests that over 300 million individuals were affected with rare diseases as of 2023 globally. Fluorescence in situ hybridization (FISH) is a genetic testing technique used by pathologists to aid in diagnosing diseases attributed to chromosomal abnormalities. Therefore, the growing genetic and rare diseases contribute to the extensive use of in situ hybridization which is expected to drive the market growth.
According to data cited by the World Health Organization in 2022, around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020 around the world.
As per data published by Global Cancer Observatory in 2021, around 544,352 cases of non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020 worldwide. As per the same source, around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020 across the globe. In situ hybridization serves as a valuable tool in examining changes in gene expression or chromosomal irregularities linked to cancer, aiding in the discovery of potential diagnostic indicators and targets for therapeutic intervention, thereby driving market growth.
The rising cases of infectious diseases such as HIV, hepatitis, and others is another key driver for the in situ hybridization (ISH) market. In situ hybridization (ISH) amalgamates laboratory medicine with molecular genetics technology to detect infectious pathogens. Fluorescence in situ hybridization (FISH) specifically aids in identifying and pinpointing nucleotide sequences within diverse samples, all while maintaining the integrity of cellular structures. According to the World Health Organization (WHO) 2022, it was estimated that around 354 million people were living with Hepatitis B or C infections in 2022 globally.
Government support and funding are directed towards maximizing the value derived from the Rare Diseases Partnership, with the overarching goal of fostering increased levels of research and innovation in the field of rare diseases. For instance, in September 2023, UK Research and Innovation, the investment, totaling nearly USD 798.5 million (GBP 627 million), encompasses various initiatives aimed at advancing rare disease research. Notably, USD 126.9 million (GBP 99.7 million) had been allocated to MRC fellowships and NIHR career development awards between 2016 and 2021, illustrating the comprehensive support network surrounding rare disease research efforts.
However, the in situ hybridization market may face growth constraints due to various factors, including the inefficiency of detecting DNA level rearrangements and chromosome pairs and concerns regarding potential exposure to radioactivity.
In Situ Hybridization Market Segment Analysis:
In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the technology segment of the in situ hybridization market, the fluorescence in situ hybridization (FISH) category is estimated to account for a significant revenue share in the in situ hybridization market in 2024. This is attributed to the growing use of FISH in cancer diagnosis and research. In oncology, FISH is utilized to identify genetic changes linked with cancer, including gene amplifications, deletions, and rearrangements of chromosomes. Fluorescence in situ hybridization (FISH) is mainly used in the diagnosis, categorization, prognosis, and anticipation of treatment outcomes in cancer patients.
The application of FISH spans a broad spectrum of scientific disciplines, including genetic counseling, subcellular studies, detection and localization of chromosome mutations, species identification, biomedical research, clinical diagnosis, toxicology, chromosomal biology, and comparative genomics.
Key players in the market are developing innovative kits and reagents for fluorescence in situ hybridization (FISH) procedures. For instance, in December 2021, BioGenex, a US-based molecular pathology company launched NanoVIP. NanoVIP is a compact, fully automated bench-top system equipped with visualization kits designed for fluorescence in situ hybridization (FISH) and in-situ hybridization (ISH). Its 10-slide design ensures reliability through automation, featuring eXACT(TM) temperature control modules for individual slide positions, precise management of reaction times, and liquid level sensors for accurate liquid handling. This meticulous control ensures the delivery of clean, intense, reliable, and reproducible stains, minimizing the need for repeat procedures.
Further, in cellular biology and neuroscience, scientists utilize techniques such as fluorescence in situ hybridization (FISH) to investigate the expression, localization, and dynamics of genes within cells and tissues. This method allows for the visualization of specific genes or RNA molecules in various cell types including neuronal cells, glial cells, and others. By studying gene expression patterns and their spatial distribution, researchers gain valuable insights into brain function, development, and the underlying mechanisms of neurological disorders. Additionally, FISH can aid in the diagnosis of genetic disorders by enabling the visualization of specific chromosomal regions or genes associated with these conditions. Therefore, the wide applications of the fluorescence in situ hybridization (FISH) category is expected to contribute to the growth of the segment, thereby driving the growth of the in situ hybridization market during the forecast period.
North America is expected to dominate the Overall In-Situ Hybridization Market:
North America is estimated to dominate the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the region further propels the expansion of the North America in situ hybridization market.
Fluorescence in situ hybridization (FISH) is a diagnostic test that maps the genetic material within human cells, pinpointing specific genes or gene segments. Due to its capability to detect genetic abnormalities linked to cancer, FISH serves as a valuable tool in diagnosing certain types of the disease. For instance, according to the National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States.
According to the Centers for Disease Control and Prevention (CDC) in May 2024, approximately 5,700 babies were born with Down syndrome each year in the United States. This equates to a prevalence of about 1 in every 640 babies. In situ hybridization is used to identify an extra chromosome or an extra piece of a chromosome for diagnosis of Down syndrome. Therefore, the growing prevalence of rare and genetic diseases is expected to drive the market growth in the region.
In Situ Hybridization Market Key Players:
Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.
Recent Developmental Activities in the In-Situ Hybridization Market:
In January 2024, Biocare Medical, LLC, a US-based tissue diagnostic company announced its collaboration with Molecular Instruments to develop automated bioimaging. This partnership combines Biocare Medical's proficiency in automated bioimaging systems with MI's array of advanced HCR(TM) Products, establishing a new benchmark in automated in situ hybridization (ISH) and immunohistochemistry (IHC).
In May 2023, Bio-Techne, a US-based life sciences company launched Advanced Cell Diagnostics (ACD)-branded RNAscope(TM) in situ hybridization (ISH). RNAscope HiPlex12 Flex Kit allows for the visualization of highly multiplexed RNA biomarkers utilizing the Hyperion XTi or previous versions of the Hyperion Imaging System. This cutting-edge system facilitates the simultaneous detection and precise quantification of over 40 biomarkers from any tissue sample in a single imaging step, employing Imaging Mass Cytometry.
In November 2022, Biocare Medical, LLC completed the acquisition of Empire Genomics, a molecular biomarkers company pioneering in cancer research and diagnostics. This acquisition serves to complement our extensive portfolio of IHC antibodies, comprehensive molecular menu, and sophisticated automation platform.
In January 2022, Bio-Techne announced its partnership with Akoya Biosciences, Inc. to develop a single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples. Through this agreement, both companies worked to develop an automated spatial multiomics workflow capable of conducting rapid, in situ analysis of multiple analytes at single-cell resolution across entire slides.
Key Takeaways from the In Situ Hybridization Market Report Study
Market size analysis for current In Situ Hybridization Market size (2024), and market forecast for 8 years (2025 to 2032)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global In Situ Hybridization market.
Various opportunities available for the other competitors in the In Situ Hybridization Market space.
What are the top-performing segments in 2024? How these segments will perform in 2032?
Which are the top-performing regions and countries in the current In Situ Hybridization market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for In Situ Hybridization market growth in the coming future?
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS IN SITU HYBRIDIZATION MARKET REPORT STUDY
In Situ Hybridization product providers
Research organizations and consulting companies
In Situ Hybridization related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in In Situ Hybridization
Various end-users who want to know more about the In Situ Hybridization Market and the latest technological developments in the In Situ Hybridization Market.
FREQUENTLY ASKED QUESTIONS FOR THE IN SITU HYBRIDIZATION MARKET:
1. What is In Situ Hybridization?
In situ hybridization (ISH) is a method in molecular biology utilized to identify and pinpoint specific nucleic acid sequences within fixed tissues, cells, or organisms. It involves pairing a labelled nucleic acid probe, complementary to the target sequence, with the sample. This probe, often tagged with a fluorescent dye, radioactive label, or another identifiable marker, binds to its complementary sequence in the sample. Following hybridization, the location of the probe within the sample is observed using microscopy or autoradiography, offering insights into the spatial arrangement of RNA or DNA molecules and facilitating the examination of gene expression patterns, chromosomal structure, and cellular interactions.
2. What is the market for In Situ Hybridization?
The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032.
3. What are the drivers for the In Situ Hybridization market?
The in situ hybridization market is slated to witness prosperity owing to factors such as the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.
4. Who are the key players operating in the In Situ Hybridization market?)
Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.
5. Which region has the highest share in the In Situ Hybridization market?
North America is estimated to dominate in the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the area further propels the expansion of the North America in situ hybridization market.
Table of Contents
1. In Situ Hybridization Market Report Introduction
1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption
2. In Situ Hybridization Market Executive Summary
2.1. Market at Glance
3. Competitive Landscape
4. Regulatory Analysis
4.1. The United States
4.2. Europe
4.3. Japan
4.4. China
5. In Situ Hybridization Market Key Factors Analysis
5.1. In Situ Hybridization Market Drivers
5.1.1. The escalating prevalence of cancer and genetic diseases.
5.1.2. The upward trend in neurological disorders and infectious diseases
5.1.3. The intensifying R&D activities and funding
5.2. In Situ Hybridization Market Restraints and Challenges
5.2.1. High cost associated with in situ hybridization assays
5.2.2. Concerns regarding potential exposure to radioactivity
5.3. In Situ Hybridization Market Opportunity
5.3.1. Focus towards automation in in situ hybridization (ISH)
5.3.2. Integration of artificial intelligence and deep learning in diagnostics
6. In Situ Hybridization Market Porter's Five Forces Analysis
6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry
7. In Situ Hybridization Market Assessment
7.1. By Product Type
7.1.1. Instruments
7.1.2. Reagents and Kits
7.1.3. Software
7.2. By Technology
7.2.1. Fluorescence In Situ Hybridization (FISH)
7.2.2. Chromogenic In Situ Hybridization (CISH)
7.2.3. Others
7.3. By Application
7.3.1. Cancer Diagnosis
7.3.2. Genetic Diseases
7.3.3. Infectious Diseases
7.3.4. Others
7.4. By End-User
7.4.1. Hospitals and Clinics
7.4.2. Diagnostic Centers
7.4.3. Pharmaceutical And Biotechnology Companies
7.4.4. Academic and Government Institutes
7.4.5. Others
7.5. By Geography
7.5.1. North America
7.5.1.1. United States In Situ Hybridization Market Size in USD million (2022-2032)
7.5.1.2. Canada In Situ Hybridization Market Size in USD million (2022-2032)
7.5.1.3. Mexico In Situ Hybridization Market Size in USD million (2022-2032)
7.5.2. Europe
7.5.2.1. France In Situ Hybridization Market Size in USD million (2022-2032)
7.5.2.2. Germany In Situ Hybridization Market Size in USD million (2022-2032)
7.5.2.3. United Kingdom In Situ Hybridization Market Size in USD million (2022-2032)
7.5.2.4. Italy In Situ Hybridization Market Size in USD million (2022-2032)
7.5.2.5. Spain In Situ Hybridization Market Size in USD million (2022-2032)
7.5.2.6. Rest of Europe In Situ Hybridization Market Size in USD million (2022-2032)
7.5.3. Asia-Pacific
7.5.3.1. China In Situ Hybridization Market Size in USD million (2022-2032)
7.5.3.2. Japan In Situ Hybridization Market Size in USD million (2022-2032)
7.5.3.3. India In Situ Hybridization Market Size in USD million (2022-2032)
7.5.3.4. Australia In Situ Hybridization Market Size in USD million (2022-2032)
7.5.3.5. South Korea In Situ Hybridization Market Size in USD million (2022-2032)
7.5.3.6. Rest of Asia-Pacific In Situ Hybridization Market Size in USD million (2022-2032)
7.5.4. Rest of the World (RoW)
7.5.4.1. Middle East In Situ Hybridization Market Size in USD million (2022-2032)
7.5.4.2. Africa In Situ Hybridization Market Size in USD million (2022-2032)
7.5.4.3. South America In Situ Hybridization Market Size In USD Million (2022-2032)
8. In Situ Hybridization Market Company and Product Profiles
